Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Saved in:
| Title: | Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. |
|---|---|
| Authors: | Hobor S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Al Bakir M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Hiley CT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.; Department of Medical Oncology, University College London Hospitals, 235 Euston Rd, Fitzrovia, London, NW1 2BU, UK., Skrzypski M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.; Department of Medical Oncology, University College London Hospitals, 235 Euston Rd, Fitzrovia, London, NW1 2BU, UK.; Department of Oncology and Radiotherapy, Medical University of Gdańsk, ul. Mariana Smoluchowskiego 17, 80-214, Gdańsk, Poland., Frankell AM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK., Bakker B; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.; European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, A. Deusinglaan 1, Groningen, 9713, the Netherlands., Watkins TBK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Markovets A; Oncology Data Science, Oncology R&D, AstraZeneca, Boston, MA, USA., Dry JR; Late Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Brown AP; Late Development, Oncology R&D, AstraZeneca, Boston, MA, USA., van der Aart J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., van den Bos H; European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, A. Deusinglaan 1, Groningen, 9713, the Netherlands., Spierings D; European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, A. Deusinglaan 1, Groningen, 9713, the Netherlands., Oukrif D; Research Department of Pathology, University College London Medical School, University Street, London, WC1E 6JJ, UK., Novelli M; Research Department of Pathology, University College London Medical School, University Street, London, WC1E 6JJ, UK., Chakrabarti T; Department of Medicine, University of California, San Francisco, CA, 94158, USA., Rabinowitz AH; Furlong Laboratory, EMBL Meyerhofstraße 1, 69117, Heidelberg, Germany., Ait Hassou L; European Organization for Research and Treatment of Cancer, Brussels, Belgium., Litière S; Bioinformatics & Biostatistics; Francis Crick Institute, London, UK., Kerr DL; Department of Medicine, University of California, San Francisco, CA, 94158, USA., Tan L; Department of Medicine, University of California, San Francisco, CA, 94158, USA., Kelly G; Bioinformatics & Biostatistics; Francis Crick Institute, London, UK., Moore DA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.; Department of Cellular Pathology, University College London Hospitals, London, UK., Renshaw MJ; Advanced Light Microscopy, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Venkatesan S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Hill W; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Huebner A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Martínez-Ruiz C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Black JRM; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Wu W; Department of Medicine, University of California, San Francisco, CA, 94158, USA., Angelova M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Downward J; Oncogene Biology Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Chmielecki J; Late Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Barrett C; Late Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Litchfield K; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Chew SK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK., Blakely CM; Department of Medicine, University of California, San Francisco, CA, 94158, USA., de Bruin EC; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Foijer F; European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, A. Deusinglaan 1, Groningen, 9713, the Netherlands., Vousden KH; p53 and Metabolism Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK., Bivona TG; Department of Medicine, University of California, San Francisco, CA, 94158, USA.; Chan-Zuckerberg Biohub, San Francisco, USA., Hynds RE; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK., Kanu N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK. n.kanu@ucl.ac.uk., Zaccaria S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK. s.zaccaria@ucl.ac.uk.; Computational Cancer Genomics Research Group, University College London Cancer Institute, London, UK. s.zaccaria@ucl.ac.uk., Grönroos E; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK. Eva.Gronroos@crick.ac.uk., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK. Charles.Swanton@crick.ac.uk.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK. Charles.Swanton@crick.ac.uk.; Department of Medical Oncology, University College London Hospitals, 235 Euston Rd, Fitzrovia, London, NW1 2BU, UK. Charles.Swanton@crick.ac.uk. |
| Corporate Authors: | TRACERx consortium |
| Source: | Nature communications [Nat Commun] 2024 Jun 13; Vol. 15 (1), pp. 4871. Date of Electronic Publication: 2024 Jun 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-47606-9 |
